Sanofi will remain disciplined, but still on the lookout for another mid-sized acquisition that can bring value to the French drug maker and further aid its quest to diversify into promising therapy areas, notably oncology and immunology, its chief executive said when presenting the group's third quarter earnings report.
In terms of M&A and its place within the company's strategy to build its portfolio, Brandicourt said, "We were disappointed...








